Balance Sheets April 30, 2024 and 2023

	2024		Restated 2023
ASSETS			
Current assets: Cash and cash equivalents Patient accounts receivable, net of estimated uncollectibles of \$1,533,000 in 2024 and	\$ 5,632,000	\$	4,944,000
\$1,948,000 in 2023 Estimated third-party payor settlements Supplies Other current assets	 1,423,000 694,000 217,000 849,000	_	1,331,000 806,000 231,000 1,379,000
Total current assets	 8,815,000	_	8,691,000
Noncurrent cash and investments: Held by trustee under indenture agreement	 1,861,000	_	1,695,000
Capital assets: Land Depreciable, net of accumulated depreciation Intangible right-to-use lease assets and subscription	68,000 9,567,000		68,000 9,837,000
IT assets, net of accumulated amortization	4,177,000	_	906,000
Total capital assets, net	 13,812,000		10,811,000
Total assets	\$ 24,488,000	\$	21,197,000

Balance Sheets, Continued April 30, 2024 and 2023

		2024	Restated 2023
LIABILITIES AND NET POSIT	ION		
Current liabilities: Current maturities of long-term debt Current maturities of lease and subscription IT liabilities Accounts payable Accrued expenses	\$	587,000 456,000 340,000 912,000	\$ 570,000 267,000 421,000 1,146,000
Total current liabilities		2,295,000	2,404,000
Long-term debt, net of current maturities Lease and subscription IT liabilities, net of current maturities		8,436,000 3,799,000	 9,023,000 620,000
Total liabilities		14,530,000	 12,047,000
Net position: Net investment in capital assets Restricted Unrestricted Total net position		534,000 1,861,000 7,563,000 9,958,000	 331,000 1,695,000 7,124,000 9,150,000
Total liabilities and net position	\$	24,488,000	\$ 21,197,000

Statements of Revenues, Expenses and Changes in Net Position Years Ended April 30, 2024 and 2023

	<u>2024</u>	Restated 2023
Operating revenues: Net patient service revenue (net of provision for bad		
debts of \$1,498,000 in 2024 and \$913,000 in 2023) Other revenue	\$ 14,452,000 1,745,000	\$ 14,895,000 1,825,000
Total operating revenues	16,197,000	16,720,000
Operating expenses: Salaries and wages Employee benefits Physician fees Medical supplies and drugs Purchased services Repairs and maintenance Utilities and communications Insurance Other operating expenses Depreciation and amortization	8,290,000 1,787,000 592,000 886,000 2,295,000 459,000 481,000 221,000 543,000 1,698,000	8,185,000 1,667,000 599,000 1,122,000 2,532,000 462,000 468,000 217,000 986,000 1,299,000
Total operating expenses	17,252,000	17,537,000
Operating loss	(1,055,000)	(817,000)
Nonoperating revenues (expenses): Investment income Interest expense Noncapital grants, contributions and other Grant stimulus funding Gain on sale of assets	284,000 (442,000) 1,008,000 73,000 22,000	26,000 (339,000) 1,179,000 1,503,000
Total nonoperating revenues	945,000	2,369,000
Excess revenues (expenses) before capital contributions	(110,000)	1,552,000
Capital contributions	918,000	495,000
Increase in net position	808,000	2,047,000
Net position, beginning of year, as originally reported	9,116,000	7,103,000
Implementation of GASB 96	34,000	
Net position, beginning of year, restated	9,150,000	7,103,000
Net position, end of year, restated	\$ 9,958,000	\$ 9,150,000

Statements of Cash Flows Years Ended April 30, 2024 and 2023

	<u>2024</u>	Restated 2023
Cash flows from operating activities: Receipts from and on behalf of patients Payments to suppliers and contractors Payments to employees	\$ 16,661,000 (5,458,000) (10,311,000)	\$ 15,561,000 (6,772,000) (9,763,000)
Net cash provided (used) by operating activities	892,000	(974,000)
Cash flows from noncapital financing activities: Noncapital grants, contributions and other Grant stimulus funding	1,008,000 73,000	1,179,000 634,000
Net cash provided by noncapital financing activities	1,081,000	1,813,000
Cash flows from capital and related financing activities: Principal paid on debt Interest paid on debt Principal paid on lease and subscription IT liabilities Interest paid on lease and subscription IT liabilities Capital contributions Purchase of capital assets Proceeds from sale of capital assets	(570,000) (275,000) (580,000) (167,000) 918,000 (751,000) 22,000	(554,000) (298,000) (358,000) (39,000) 495,000 (1,500,000)
Net cash used by capital and related financing activities	(1,403,000)	(2,254,000)
Cash flows from investing activities: Investment income	284,000	26,000
Net cash provided by investing activities	284,000	26,000
Net increase (decrease) in cash and cash equivalents	854,000	(1,389,000)
Cash and cash equivalents, beginning of year	6,639,000	8,028,000
Cash and cash equivalents, end of year	\$ 7,493,000	\$ 6,639,000

Statements of Cash Flows, Continued Years Ended April 30, 2024 and 2023

	<u>2024</u>		Restated 2023
Reconciliation of cash and cash equivalents to the balance sheet:			
Cash and cash equivalents in current assets Held by trustee under indenture	\$ 5,632,000 1,861,000	\$ —	4,944,000 1,695,000
Total cash and cash equivalents	\$ 7,493,000	\$	6,639,000
Reconciliation of operating loss to net cash flows provided (used) by operating activities:			
Operating loss Adjustments to reconcile operating loss	\$ (1,055,000)	\$	(817,000)
to net cash provided (used) by operating activities: Depreciation and amortization Provision for bad debts	1,698,000 1,498,000		1,299,000 913,000
Changes in: Patient accounts receivable Supplies Estimated third-party payor settlements Other current assets Accounts payable Accrued expenses	(1,590,000) 14,000 112,000 530,000 (81,000) (234,000)		(967,000) (29,000) (707,000) (617,000) (138,000) 89,000
Net cash provided (used) by operating activities	\$ 892,000	\$	(974,000)

Supplemental disclosure of cash flow information:

The Authority entered into lease obligations of approximately \$0 and \$131,000 for new equipment in 2024 and 2023, respectively.

The Authority entered into subscription IT obligations of approximately \$3,907,000 and \$595,000 in 2024 and 2023, respectively.